Table 2.
Number and Percentage of Antibiotic-associated Adverse Drug Events (ADEs) in 689 Hospitalized Patients Undergoing Systemic Administration of Broad-spectrum Antibiotics.
| Broad-spectrum antibiotics | No. of patients receiving the agents | No. (%) of patients with ADEs | Duration, [median days] | No. (%) [Median day to developing ADEs] | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac | Gastrointestinal | Hepatobiliary | Renal | Neurologic | Hematologic | Dermatologic | Anaphylactic | Muscular | CDI | ||||
| Piperacillin/ Tazobactam |
242 | 50 (20.7) | [7] | 0 | 26 (10.7) [6] | 7 (2.9) [9] | 10 (4.1) [7.5] | 0 | 4 (1.7) | 6 (2.5) [5] | 1 | 0 | 0 |
| Carbapenems | 235 | 37 (15.7) | 0 | 16 (6.8) [10.5] | 15 (6.4) [9] | 0 | 0 | 1 (0.4) | 5 (2.1) [11] | 0 | 0 | 0 | |
| Meropenem | 181 | 29 (16.0) | [8] | 0 | 12 (6.6) [9.5] | 13 (7.2) [9] | 0 | 0 | 1 (0.6) | 3 (1.7) | 0 | 0 | 1 (0.6) |
| Doripenem | 52 | 8 (15.4) | [9.5] | 0 | 4 (7.7) | 2 (3.8) | 0 | 0 | 0 | 2 (3.8) | 0 | 0 | 0 |
| Imipenem | 2 | 0 | n.p. | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Anti-MRSA drugs | |||||||||||||
| Vancomycin† | 92 | 18 (19.6) | [8] | 0 | 1 (1.1) | 4 (4.3) | 6 (6.5) [15.5] | 0 | 5 (5.4) [12] | 2 (2.2) | 0 | 0 | 0 |
| Teicoplanin | 55 | 6 (10.9) | [7] | 0 | 1 (1.8) | 1 (1.8) | 0 | 0 | 0 | 2 (3.6) | 0 | 0 | 0 |
| Daptomycin | 51 | 6 (11.8) | [11] | 0 | 0 | 2 (3.9) | 0 | 0 | 1 (2.0) | 2 (3.9) | 0 | 2 (3.9) | 0 |
| Linezolid | 14 | 1 (7.1) | [7.5] | 0 | 0 | 0 | 0 | 0 | 1 (7.1) | 0 | 0 | 0 | 0 |
| Total | 689 | 118 (17.1) | 0 | 44 (6.4) | 29 (4.2) | 16 (2.3) | 0 | 12 (1.7) | 17 (2.5) | 1 (0.1) | 2 (0.3) | 1 (0.1) | |
†intravenous administration only. Median days to developing ADEs were displayed for those with more than 5 cases of ADEs. CDI: Clostridiumdifficile infection, IQR: interquartile range, MRSA: methicillin-resistant Staphylococcusaureus, n.p.: not applicable